Get the Stockscreener App
2.75
1.48%
0.04
After Hours:
2.75
Galectin Therapeutics Inc stock is traded at $2.75, with a volume of 65,411.
It is up +1.48% in the last 24 hours and up +2.04% over the past month.
See More
Previous Close:
$2.71
Open:
$2.72
24h Volume:
65,411
Relative Volume:
0.40
Market Cap:
$138.59M
Revenue:
-
Net Income/Loss:
$-41.07M
P/E Ratio:
-4.1667
EPS:
-0.66
Net Cash Flow:
$-32.97M
1W Performance:
+1.10%
1M Performance:
+2.04%
6M Performance:
+15.06%
1Y Performance:
+43.23%
1-Day Range:
$2.72
$2.8345
1-Week Range:
$2.55
$2.8345
52-Week Range:
$1.555
$4.2684
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference - The Manila Times
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference - StockTitan
Galectin Therapeutics (FRA:PHPN) Interest Expense : €-3.71 Mil (TTM As of Jun. 2024) - GuruFocus.com
Galectin Therapeutics (FRA:PHPN) Change In Prepaid Assets : €-0.16 Mil (TTM As of Jun. 2024) - GuruFocus.com
StockNews.com Lowers Galectin Therapeutics (NASDAQ:GALT) to Sell - MarketBeat
Bank of New York Mellon Corp Purchases Shares of 64,423 Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin 3 Market: Report Trends and Future Forecast Until (2024-2034) - Apiculture Market: Report ...
Global Non Alcoholic Steatohepatitis Market to Hit $ 108428.91 Million by 2032, Growing at 60.1% CAGR - 대구포스트
Galectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.com - MarketBeat
Galectin Therapeutics (FRA:PHPN) Enterprise Value : €217.44 Mil (As of Sep. 21, 2024) - GuruFocus.com
Galectin Therapeutics (NASDAQ:GALT) Upgraded to “Hold” at StockNews.com - Defense World
Cirrhosis Pipeline Insights, Clinical Trials, Treatment Drugs, and Companies 2024 - openPR
Commonwealth Equity Services LLC Buys 367,610 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Commonwealth Equity Services LLC Purchases 367,610 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat
Head-To-Head Analysis: Galera Therapeutics (NASDAQ:GRTX) & Galectin Therapeutics (NASDAQ:GALT) - Defense World
Non-Alcoholic Steatohepatitis Treatment Market Insights Discussed Regarding Report 2024: Detailed Analysis ... - WhaTech
Galectin Therapeutics Unveils Future Plans and Drug Potential - TipRanks
Hepatic Cirrhosis Market: Epidemiology, Therapies, - openPR
Short Interest in Galectin Therapeutics Inc. (NASDAQ:GALT) Increases By 6.4% - Defense World
North America Galectin Inhibitor Therapeutics Market By Application : Industry Analysis and Forecast 2031 - அக்னி செய்திகள்
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Galectin Therapeutics Inc. (NASDAQ:GALT) Sees Significant Growth in Short Interest - MarketBeat
Its Stock Has Paid Off Big Time For Galectin Therapeutics Inc - SETE News
How did Galectin Therapeutics Inc (GALT) fare last session? - US Post News
Investors Buy Large Volume of Put Options on Galectin Therapeutics (NASDAQ:GALT) - Defense World
Stock Traders Purchase Large Volume of Put Options on Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
Galectin Therapeutics executive buys $8,050 in company stock By Investing.com - Investing.com Australia
Galectin Therapeutics executive buys $8,050 in company stock - Investing.com India
Galectin Therapeutics executive buys $8,050 in company stock By Investing.com - Investing.com Canada
Galectin Therapeutics executive buys $8,050 in company stock - Investing.com
Galectin Therapeutics executive buys $8,050 in company stock By Investing.com - Investing.com UK
Analysts Set Expectations for Galectin Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:GALT) - MarketBeat
HC Wainwright Comments on Galectin Therapeutics Inc.’s Q1 2025 Earnings (NASDAQ:GALT) - Defense World
GALT (Galectin Therapeutics) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Acquired by Vanguard Group Inc. - Defense World
GALT (Galectin Therapeutics) Dividends per Share : $0.00 (TTM As of Jun. 2024) - GuruFocus.com
GALT (Galectin Therapeutics) Short-Term Capital Lease Obligation : $0.04 Mil (As of Jun. 2024) - GuruFocus.com
HC Wainwright Reaffirms "Buy" Rating for Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Galectin Therapeutics (NASDAQ:GALT) - Defense World
Galectin Therapeutics (NASDAQ:GALT) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Galectin Therapeutics (STU:PHPN) EV-to-Revenue : (As of Aug. 15, 2024) - GuruFocus.com
GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update - BioSpace
Galectin Flat on Quarterly Figures - Baystreet.ca
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update - StockTitan
Galectin Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - XM
Global Next-Generation Complement Therapeutics Market to Surge Significantly at a CAGR of ~15% by 2030 | DelveInsight - India Shorts
Galectin Therapeutics (NASDAQ:GALT) & Can-Fite BioPharma (NYSE:CANF) Critical Comparison - Defense World
Liver Fibrosis Drugs Market Size 2032 | Inventiva Pharma, Galmed - openPR
Galectin Therapeutics Appoints Khurram Jamil, M.D. To Chief Medical Officer - citybiz
Galectin Therapeutics Appoints New Chief Medical Officer - TipRanks
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):